Skip Navigation

JNCI Journal of the National Cancer Institute 2002 94(13):960-961; doi:10.1093/jnci/94.13.960
© 2002 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Hedenfalk, I. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hedenfalk, I. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 94, No. 13, 960-961, July 3, 2002
© 2002 Oxford University Press

EDITORIAL

Gene Expression Profiling of Hereditary and Sporadic Ovarian Cancers Reveals Unique BRCA1 and BRCA2 Signatures

Ingrid A. Hedenfalk

Correspondence to: Ingrid Hedenfalk, Ph.D., Cancer Genetics Branch, National Human Genome Research Institute, National Institutes of Health, 50 South Dr., MSC 8000, Bethesda, MD 20892.

The first 10% of the full text of this article appears below.

The recent completion of the draft human genome sequence (1) presents countless opportunities to investigate genome function and the importance of alterations in the genetic code in both health and disease. Among the most rapidly adopted of the emerging genomic technologies, microarray hybridization permits the parallel determination of the expression of tens of thousands of genes in tissue samples (2). Microarray studies have proven to be of great value in further understanding the basic biology of cancer and have been used successfully to classify tumors into distinct, clinically relevant subgroups based on gene expression profiles and to identify potential biomarkers. Ovarian cancers differ from many other human tumors in displaying considerable disease heterogeneity, a poorly understood progression pathway, and few good tumor markers. In addition, ovarian cancers are usually diagnosed . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Mol. Cell. Biol.Home page
J. M. Stark, A. J. Pierce, J. Oh, A. Pastink, and M. Jasin
Genetic Steps of Mammalian Homologous Repair with Distinct Mutagenic Consequences
Mol. Cell. Biol., November 1, 2004; 24(21): 9305 - 9316.
[Abstract] [Full Text] [PDF]